Pluri (PLUR) Income from Continuing Operations (2010 - 2025)
Pluri (PLUR) posted quarterly Income from Continuing Operations of 6872000.0 for Q4 2025, down 120.96% year-over-year from 32779018.4 in Q4 2024, and down 12.07% quarter-over-quarter from 6132000.0 in Q3 2025.
Pluri (PLUR) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Pluri (PLUR) has reported Income from Continuing Operations for 16 consecutive years, with 6872000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 120.96% year-over-year to 6872000.0; the TTM figure through Dec 2025 stood at 25470000.0 (down 19.45% YoY), while the FY2025 annual figure was 23250000.0, down 8.93% from the prior year.
- Income from Continuing Operations retreated to 6872000.0 in Q4 2025 per PLUR's latest filing, from 6132000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3110000.0 in Q4 2024 and bottomed at 14648000.0 in Q2 2021.
- Historically, Income from Continuing Operations has averaged 7896200.0 across 5 years, with a median of 6658500.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations surged 44.57% — and 2025, when it tumbled 120.96%.
- Pluri's Income from Continuing Operations stood at 11165000.0 in 2021, then grew by 24.17% to 8466000.0 in 2022, then surged by 35.87% to 5429000.0 in 2023, then surged by 42.72% to 3110000.0 in 2024, then plunged by 120.96% to 6872000.0 in 2025.
- Business Quant data shows PLUR's Income from Continuing Operations at 6872000.0 in Q4 2025, 6132000.0 in Q3 2025, and 6854000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | -6.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.87 Mn |
| Sep 30, 2025 | -6.13 Mn |
| Jun 30, 2025 | -6.85 Mn |
| Mar 31, 2025 | -5.61 Mn |
| Dec 31, 2024 | -3.11 Mn |
| Sep 30, 2024 | -6.04 Mn |
| Jun 30, 2024 | -6.25 Mn |
| Mar 31, 2024 | -5.92 Mn |
| Dec 31, 2023 | -5.43 Mn |
| Sep 30, 2023 | -5.59 Mn |
| Jun 30, 2023 | -5.98 Mn |
| Mar 31, 2023 | -7.98 Mn |
| Dec 31, 2022 | -8.47 Mn |
| Sep 30, 2022 | -6.46 Mn |
| Jun 30, 2022 | -9.17 Mn |
| Mar 31, 2022 | -10.14 Mn |
| Dec 31, 2021 | -11.17 Mn |
| Sep 30, 2021 | -11.66 Mn |
| Jun 30, 2021 | -14.65 Mn |
| Mar 31, 2021 | -14.44 Mn |